Literature DB >> 18808450

Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum.

Xuesong Chen1, Xun Lan, Ian Roche, Rugao Liu, Jonathan D Geiger.   

Abstract

The blood-brain barrier (BBB) is important physiologically. Pathologically, BBB disruption has been implicated in a wide spectrum of neurological disorders including Parkinson's disease (PD). Recent studies indicate that caffeine is protective against PD, but by poorly understood mechanisms. Using a MPTP neurotoxin model of PD we tested the hypothesis that the protective actions of caffeine were because of, at least in part, preventing MPTP-induced BBB dysfunction. FVB mice were pre-treated with caffeine (10 mg/kg, i.p.) or saline for 7 days prior to initiation of neurotoxin treatments; during the 7 days of neurotoxin treatment, caffeine or saline continued to be administered 10 min before each dose of MPTP (20 mg/kg, i.p.). Striatum (and for some studies hippocampus and cerebral cortex as well) were evaluated for BBB leakage, tight junction protein expression levels, integrity of dopaminergic neurons, and activation of astrocytes and microglia using immunostaining, immunoblotting and real-time PCR techniques. We found that caffeine blocked MPTP-induced decreases in numbers of tyrosine hydroxylase-positive dopaminergic neurons, increases in leakage of Evan's blue dye and FITC-albumin in striatum but not in cerebral cortex or hippocampus, decreases in levels of the tight junction proteins occludin and ZO-1, and increases in reactive gliosis. Our results suggest that caffeine might protect against PD and PD-like features in animal models, in part, by stabilizing the BBB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18808450      PMCID: PMC3692355          DOI: 10.1111/j.1471-4159.2008.05697.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  68 in total

Review 1.  Blood-brain barrier disruption in multiple sclerosis.

Authors:  Alireza Minagar; J Steven Alexander
Journal:  Mult Scler       Date:  2003-12       Impact factor: 6.312

Review 2.  Structural and functional aspects of the blood-brain barrier.

Authors:  David J Begley; Milton W Brightman
Journal:  Prog Drug Res       Date:  2003

Review 3.  Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation.

Authors:  Margaret A Petty; Eng H Lo
Journal:  Prog Neurobiol       Date:  2002-12       Impact factor: 11.685

4.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian.

Authors:  C Barcia; V Bautista; A Sánchez-Bahillo; E Fernández-Villalba; B Faucheux; M Poza y Poza; A Fernandez Barreiro; E C Hirsch; M-T Herrero
Journal:  J Neural Transm (Vienna)       Date:  2005-01-24       Impact factor: 3.575

5.  6-Hydroxydopamine-induced alterations in blood-brain barrier permeability.

Authors:  P M Carvey; C H Zhao; B Hendey; H Lum; J Trachtenberg; B S Desai; J Snyder; Y G Zhu; Z D Ling
Journal:  Eur J Neurosci       Date:  2005-09       Impact factor: 3.386

Review 6.  Coffee and health: a review of recent human research.

Authors:  Jane V Higdon; Balz Frei
Journal:  Crit Rev Food Sci Nutr       Date:  2006       Impact factor: 11.176

7.  Impaired functional recovery after stroke in the stroke-prone spontaneously hypertensive rat.

Authors:  J K McGill; L Gallagher; H V O Carswell; E A Irving; A F Dominiczak; I M Macrae
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

8.  Possible involvement of phosphorylation of occludin in tight junction formation.

Authors:  A Sakakibara; M Furuse; M Saitou; Y Ando-Akatsuka; S Tsukita
Journal:  J Cell Biol       Date:  1997-06-16       Impact factor: 10.539

9.  Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE).

Authors:  Yuri Persidsky; David Heilman; James Haorah; Marina Zelivyanskaya; Raisa Persidsky; Gregory A Weber; Hiroaki Shimokawa; Kozo Kaibuchi; Tsuneya Ikezu
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

10.  Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.

Authors:  Joan Lindsay; Danielle Laurin; René Verreault; Réjean Hébert; Barbara Helliwell; Gerry B Hill; Ian McDowell
Journal:  Am J Epidemiol       Date:  2002-09-01       Impact factor: 4.897

View more
  54 in total

Review 1.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

2.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

3.  Homeostatic bioenergetic network regulation - a novel concept to avoid pharmacoresistance in epilepsy.

Authors:  Detlev Boison; Susan A Masino; Jonathan D Geiger
Journal:  Expert Opin Drug Discov       Date:  2011-07       Impact factor: 6.098

4.  Quantification of neurovascular protection following repetitive hypoxic preconditioning and transient middle cerebral artery occlusion in mice.

Authors:  Katherine Poinsatte; Uma Maheswari Selvaraj; Sterling B Ortega; Erik J Plautz; Xiangmei Kong; Jeffrey M Gidday; Ann M Stowe
Journal:  J Vis Exp       Date:  2015-05-04       Impact factor: 1.355

5.  An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.

Authors:  Aditiben Patel; Giuseppe V Toia; Kalea Colletta; Brinda Desai Bradaric; Paul M Carvey; Bill Hendey
Journal:  Exp Neurol       Date:  2011-06-15       Impact factor: 5.330

6.  Human brain endothelial cells are responsive to adenosine receptor activation.

Authors:  Jeffrey H Mills; Leah Alabanza; Babette B Weksler; Pierre-Olivier Couraud; Ignacio A Romero; Margaret S Bynoe
Journal:  Purinergic Signal       Date:  2011-02-17       Impact factor: 3.765

7.  Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse.

Authors:  Sharawan Yadav; Satya Prakash Gupta; Garima Srivastava; Pramod Kumar Srivastava; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2011-12-27       Impact factor: 3.996

8.  Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy.

Authors:  Robert L Haining; Travis M Jones; Aubrey Hernandez
Journal:  Neurochem Res       Date:  2016-09-23       Impact factor: 3.996

Review 9.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

10.  Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice.

Authors:  Chih W Hsu; Chin S Wang; Ted H Chiu
Journal:  J Biomed Sci       Date:  2010-01-15       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.